Sandesh Mahatme has an estimated net worth of $47.2 Million. This is based on reported shares across multiple companies, which include Flexion Therapeutics Inc, Sarepta Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Stalar 4, Inc., Stalar 3 Inc., CRISPR Therapeutics AG, and Vor Biopharma Inc..

2019 was Sandesh Mahatme's most active year for acquiring shares with 26 total transactions. Sandesh Mahatme's most active month to acquire stocks was the month of May. 2019 was Sandesh Mahatme's most active year for disposing of shares, totalling 31 transactions. Sandesh Mahatme's most active month to dispose stocks was the month of July. 2019 saw Sandesh Mahatme paying a total of $9,424,882.48 for 466,789 shares, this is the most they've acquired in one year. In 2019 Sandesh Mahatme cashed out on 745,599 shares for a total of $40,092,905.85, their largest year based on trade value.